• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视神经脊髓炎谱系障碍的治疗选择

Therapeutic options in neuromyelitis optica spectrum disorders.

作者信息

Kitley Joanna, Palace Jackie

机构信息

a Department of Neurology, Wessex Neurological Centre , Southampton General Hospital , Southampton , UK.

b Nuffield Department of Clinical Neurosciences, Level 3 West Wing , Oxford University Hospitals NHS Trust, University of Oxford , Oxford , UK.

出版信息

Expert Rev Neurother. 2016;16(3):319-29. doi: 10.1586/14737175.2016.1150178.

DOI:10.1586/14737175.2016.1150178
PMID:26840802
Abstract

Neuromyelitis optica is a relapsing inflammatory disorder of the central nervous system that manifests predominantly with attacks of optic neuritis and longitudinally extensive transverse myelitis; attacks are often severe. In contrast to multiple sclerosis, a secondary progressive phase is rare, and disability in neuromyelitis optica spectrum disorders is related to relapses. Thus, prompt and effective treatment of relapses, and early initiation of long-term immunosuppression to prevent subsequent attacks is required in order to prevent morbidity and mortality.

摘要

视神经脊髓炎是一种中枢神经系统的复发性炎性疾病,主要表现为视神经炎发作和纵向广泛横贯性脊髓炎;发作通常较为严重。与多发性硬化症不同,继发进展期罕见,视神经脊髓炎谱系疾病中的残疾与复发有关。因此,为预防发病和死亡,需要迅速有效地治疗复发,并尽早开始长期免疫抑制以预防后续发作。

相似文献

1
Therapeutic options in neuromyelitis optica spectrum disorders.视神经脊髓炎谱系障碍的治疗选择
Expert Rev Neurother. 2016;16(3):319-29. doi: 10.1586/14737175.2016.1150178.
2
Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?神经髓鞘炎的诊断和治疗的新进展:是否需要重新定义金标准?
Expert Rev Clin Immunol. 2013 Oct;9(10):979-86. doi: 10.1586/1744666X.2013.839944.
3
Treatment of Neuromyelitis Optica Spectrum Disorders.视神经脊髓炎谱系疾病的治疗。
Int J Mol Sci. 2021 Aug 11;22(16):8638. doi: 10.3390/ijms22168638.
4
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.水通道蛋白-4 免疫球蛋白 G 阳性视神经脊髓炎谱系疾病中的短节段脊髓炎病变。
JAMA Neurol. 2015 Jan;72(1):81-7. doi: 10.1001/jamaneurol.2014.2137.
5
Neuromyelitis Optica (Devic's Syndrome): an Appraisal.视神经脊髓炎(Devic 综合征):评价。
Curr Rheumatol Rep. 2016 Aug;18(8):54. doi: 10.1007/s11926-016-0599-3.
6
Neuromyelitis Optica.视神经脊髓炎
Rheum Dis Clin North Am. 2017 Nov;43(4):579-591. doi: 10.1016/j.rdc.2017.06.007. Epub 2017 Aug 31.
7
Diagnosis and management of neuromyelitis optica spectrum disorders - An update.视神经脊髓炎谱系疾病的诊断与管理——更新。
Autoimmun Rev. 2018 Mar;17(3):195-200. doi: 10.1016/j.autrev.2018.01.001. Epub 2018 Jan 13.
8
Neuromyelitis optica (Devic's syndrome).视神经脊髓炎(德维克综合征)。
Handb Clin Neurol. 2014;122:581-99. doi: 10.1016/B978-0-444-52001-2.00025-X.
9
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.AQP4-IgG 阳性视神经脊髓炎谱系疾病的预后预测模型。
Brain. 2019 May 1;142(5):1310-1323. doi: 10.1093/brain/awz054.
10
Neuromyelitis optica spectrum disorder (NMOSD): A new concept.视神经脊髓炎谱系障碍(NMOSD):一个新概念。
Rev Neurol (Paris). 2016 Apr-May;172(4-5):256-62. doi: 10.1016/j.neurol.2016.03.003. Epub 2016 May 4.

引用本文的文献

1
Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway.视神经脊髓炎谱系障碍(NMOSD)和复发性髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)中耐受性因子可溶性CD83(sCD83)降低:一种潜在的新治疗途径。
Front Immunol. 2025 Jul 24;16:1620069. doi: 10.3389/fimmu.2025.1620069. eCollection 2025.
2
Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.复发型视神经脊髓炎谱系障碍患者利妥昔单抗维持治疗的结果:一项单中心回顾性分析
Acta Neurol Belg. 2024 Dec;124(6):1847-1854. doi: 10.1007/s13760-024-02555-4. Epub 2024 Jun 11.
3
Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study.
视神经脊髓炎谱系障碍(NMOSD)相关疾病(MOGAD)与视神经脊髓炎谱系障碍(NMOSD)亚型的临床放射学特征、光学相干断层扫描参数及预后比较:一项前瞻性观察研究。
J Neurosci Rural Pract. 2023 Apr-Jun;14(2):239-251. doi: 10.25259/JNRP_8_2022. Epub 2023 Feb 23.
4
Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD.细胞疗法:治疗 NMOSD 和 MOGAD 的新兴基于细胞的治疗方法。
Int J Mol Sci. 2021 Jul 25;22(15):7925. doi: 10.3390/ijms22157925.
5
Intravenous immunoglobulin as the rescue treatment in NMOSD patients.静脉注射免疫球蛋白作为 NMOSD 患者的抢救治疗。
Neurol Sci. 2021 Sep;42(9):3857-3863. doi: 10.1007/s10072-021-05079-4. Epub 2021 Feb 1.
6
Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases.利妥昔单抗治疗难治性视神经脊髓炎谱系障碍患者的疗效及安全性:伊朗病例的前瞻性观察
Caspian J Intern Med. 2020;11(2):155-162. doi: 10.22088/cjim.11.2.155.
7
Emerging therapeutic targets for neuromyelitis optica spectrum disorder.视神经脊髓炎谱系疾病的新兴治疗靶点。
Expert Opin Ther Targets. 2020 Mar;24(3):219-229. doi: 10.1080/14728222.2020.1732927. Epub 2020 Mar 2.
8
Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.补体在重症肌无力和视神经脊髓炎谱系疾病中的作用及补体抑制剂的潜力:简要综述。
J Neurol. 2021 May;268(5):1643-1664. doi: 10.1007/s00415-019-09498-4. Epub 2019 Sep 3.
9
CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.通过他汀类药物上调星形胶质细胞中的 CD55 作为治疗水通道蛋白 4-IgG 阳性视神经脊髓炎的潜在方法。
J Neuroinflammation. 2019 Mar 9;16(1):57. doi: 10.1186/s12974-019-1448-x.
10
Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.视神经脊髓炎(NMO)中规律及维持治疗依从性的重要性:一例复发病例的经验教训
Am J Case Rep. 2018 Jan 11;19:41-46. doi: 10.12659/ajcr.906150.